FASL anticorps

N° du produit ABIN1105941

Cet anticorps anti-FASL est un anticorps Hamster Monoclonal détectant FASL dans EIA. Adapté pour Humain.

Aperçu rapide pour FASL anticorps (ABIN1105941)

Antigène: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivité: Humain

Hôte: Hamster

Clonalité: Monoclonal

Conjugué: Cet anticorp FASL est non-conjugé

Application: Enzyme Immunoassay (EIA)

Clone: 4H9

Détail du produit anti-FASL anticorps

Specificité: This antibody reacts with Fas Ligand.

Réactivité croisée (Details): Species reactivity (tested):Human

Purification: Protein A agarose

Immunogène: Recombinant human Fas Ligand

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: PBS containing 50 % glycerol, pH 7.2. Contains no preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: Store (in aliquots) at -20 °C.

Détails sur FASL

Antigène: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Autre désignation: CD178 / Fas Ligand

Sujet: Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that the Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in turn plays a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6

ID gène: 356

NCBI Accession: NP_000630

UniProt: P48023

Pathways: Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity